WESLEY BOYD: Open Payments
NPI 1386097921 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,009 in 122 payments from 22 companies in 2025. Trend: 2023 $1,544 · 2024 $1,911 · 2025 $2,009
Food & beverage: $2,009
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 42 | $540 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $219 |
| Aimmune Therapeutics, Inc. | 8 | $153 |
| PFIZER INC. | 8 | $138 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $119 |
| Janssen Biotech, Inc. | 5 | $101 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| QOL Medical, LLC | 4 | $82 |
| Lilly USA, LLC | 5 | $81 |
| Madrigal Pharmaceuticals | 3 | $71 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, LINZESS, VELSIPITY, XIFAXAN, TREMFYA, VOWST.
Industry payments across MS — which companies pay providers there.
